SCHEMBL2226053

SCHEMBL2226053

Cc1ccc(-c2nc3ccc(C)cn3c2Cn2ccnc2-c2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.57
SLC2A1 P11166 5/20 0.54
KDM4E B2RXH2 3/20 0.52
ALDH1A1 P00352 2/20 0.52
HTT P42858 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
NR1H4 Q96RI1 4/20 0.49
HPGD P15428 2/20 0.49
GABRA1 P14867 2/20 0.49
GABRB2 P47870 2/20 0.49
LMNA P02545 1/20 0.49
ALB P02768 1/20 0.49
CYP3A4 P08684 1/20 0.49
CHRM1 P11229 1/20 0.49
GABRB1 P18505 1/20 0.49
GABRG2 P18507 1/20 0.49
GABRB3 P28472 1/20 0.49
GABRA3 P34903 1/20 0.49
ADRA1A P35348 1/20 0.49
OPRK1 P41145 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2223787 0.87 GABRA1 (0.52) SMN1; SMN2SLC2A1KDM4EALDH1A1HTT
SCHEMBL2227431 0.84 GABRA1 (0.49) SMN1; SMN2SLC2A1KDM4EALDH1A1HTT
SCHEMBL2223837 0.83 GABRA1 (0.48) SMN1; SMN2SLC2A1KDM4EALDH1A1HTT
SCHEMBL2273490 0.81 GABRA1 (0.51) SMN1; SMN2SLC2A1KDM4EALDH1A1HTT
SCHEMBL1430418 0.81 SMN1; SMN2 (0.48) SMN1; SMN2SLC2A1KDM4EALDH1A1HTT
SCHEMBL2275461 0.80 SMN1; SMN2 (0.56) SMN1; SMN2SLC2A1KDM4EALDH1A1HTT
SCHEMBL2224605 0.78 GABRA1 (0.60) SMN1; SMN2SLC2A1KDM4EALDH1A1HTT
SCHEMBL2230797 0.78 PKM (0.60) SMN1; SMN2SLC2A1KDM4EALDH1A1HTT
SCHEMBL2286552 0.78 GABRA1 (0.53) SMN1; SMN2SLC2A1KDM4EALDH1A1HTT
SCHEMBL1430009 0.78 GABRA1 (0.53) SMN1; SMN2SLC2A1KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. 2013-10-31 US disclosed
US-8497278-B2 Imidazo[1,2-a]pyridine compounds SUNOVION PHARMACEUTICALS INC. (US) 2013-07-30 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD SMN1; SMN2 593/4885SLC2A1 2033/4885KDM4E 3088/4885
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD SMN1; SMN2 593/4885SLC2A1 2033/4885KDM4E 3088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.